Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization

Over 9,000 women with breast cancer are enrolled annually on clinical trials sponsored by the National Cancer Institute (NCI), accounting for about one-third of all patients enrolled on NCI-sponsored trials. Thousands are also enrolled on pharmaceutical-sponsored studies. Although breast cancer mort...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2010-02, Vol.119 (3), p.511-527
Main Authors: Sparano, Joseph A, Hortobagyi, Gabriel N, Gralow, Julie R, Perez, Edith A, Comis, Robert L
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Biomedical Research
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms, Male - drug therapy
Cancer
Cancer research
Cancer therapies
Chemotherapy
Clinical Trials as Topic
Editorial
Female
Health aspects
Health Planning Councils
Humans
Male
Medical research
Medicine
Medicine & Public Health
Mortality
Oncology
Oncology, Experimental
Practice Guidelines as Topic
Priorities
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over 9,000 women with breast cancer are enrolled annually on clinical trials sponsored by the National Cancer Institute (NCI), accounting for about one-third of all patients enrolled on NCI-sponsored trials. Thousands are also enrolled on pharmaceutical-sponsored studies. Although breast cancer mortality rates have recently declined for the first time in part due to systemic therapeutic advances, coordinated efforts will be necessary to maintain this trend. The Coalition of Cancer Cooperative Groups convened the Scientific Leadership Council in breast cancer (BC), an expert panel, to identify priorities for future research and current trials with greatest practice-changing potential. Panelists formed a consensus on research priorities for chemoprevention, development and application of molecular markers for predicting therapeutic benefit and toxicity, intermediate markers predictive of therapeutic effect, pathogenesis-based therapeutic approaches, utilization of adaptive designs requiring fewer patients to achieve objectives, special and minority populations, and effects of BC and treatment on patients and families. Panelists identified 13 ongoing studies as High Priority and identified gaps in the current trial portfolio. We propose priorities for current and future clinical breast cancer research evaluating systemic therapies that may serve to improve the efficiency of clinical trials, identify individuals most likely to derive therapeutic benefit, and prioritize therapeutic strategies.
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-009-0433-y